ABOS
NASDAQ · Biotechnology
Acumen Pharmaceuticals Inc
$2.48
-0.09 (-3.50%)
Open$2.58
Previous Close$2.57
Day High$2.62
Day Low$2.44
52W High$3.60
52W Low$0.97
Volume—
Avg Volume263.6K
Market Cap172.62M
P/E Ratio—
EPS$-2.00
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+796.0% upside
Current
$2.48
$2.48
Target
$22.22
$22.22
$18.81
$22.22 avg
$35.10
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 32.13M | 32.40M | 26.28M |
| Net Income | 3.79M | 3.97M | 2.79M |
| Profit Margin | 11.8% | 12.2% | 10.6% |
| EBITDA | 5.50M | 6.39M | 4.32M |
| Free Cash Flow | 1.86M | 2.43M | 2.61M |
| Rev Growth | +20.9% | +8.5% | +2.1% |
| Debt/Equity | 0.36 | 0.35 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |